ConverGene has entered into an exclusive license agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. Under this agreement, ConverGene has the rights to commercialize jointly developed small molecule BET bromodomain inhibitors that have a unique core structure as compared to other cancer therapeutics currently in clinical trials. This is an area of intense research and new advances are continuous in the competitive area of epigenetic control. Preliminary preclinical studies indicate that the molecules being developed with this unique core structure possess superior pharmacokinetic and toxicology properties. The first focus of ConverGene will be in the hematology oncology space followed by solid tumors. However, our molecules affect fundamental biological pathways and as such will be valuable to out-license in a variety of disease fields including inflammation, obesity, metabolic, cardiovascular, neurodegenerative, psychiatric and infectious diseases.
CEO Dr. Jeff Strovel commented, “We are delighted to be working with NCATS and see a bright future for this compound in treating a variety of diseases for which patients currently have no treatment options."
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.